Key result
Idarucizumab administration resulted in immediate, complete, and sustained reversal of the dabigatran-induced anticoagulant effect in healthy Chinese subjects, decreasing the area under the effect curve by ≥98% for all coagulation parameters.
Why the study?
This study was conducted to investigate the pharmacokinetics, pharmacodynamics, and safety of idarucizumab, and its effect on dabigatran PK and PD, in healthy Chinese subjects at dabigatran steady state.
Does idarucizumab reverse dabigatran anticoagulant activity in healthy Chinese volunteers?
Does idarucizumab reverse dabigatran anticoagulant activity in healthy Chinese volunteers?
Idarucizumab safely and completely reverses the anticoagulant effect of dabigatran in healthy Chinese volunteers, with comparable pharmacokinetics to Caucasian and Japanese populations.
Answers are grounded in this paper and cite their sources.
Supports reversal data in healthy Chinese volunteers; extends prior findings but leaves open clinical efficacy and requires patient studies.
INTRODUCTION: Idarucizumab is a humanized monoclonal antibody fragment that specifically binds to dabigatran with high affinity and reverses its anticoagulant effect. This study investigated the pharmacokinetics (PK) and pharmacodynamics (PD) of idarucizumab in healthy Chinese subjects at steady state of dabigatran and explored the effect of idarucizumab on PK and PD of dabigatran. METHODS: Twelve subjects received dabigatran etexilate treatment alone (220 mg twice daily, b.i.d., oral). After a washout period, the 12 subjects again received dabigatran etexilate (220 mg b.i.d., oral) and idarucizumab (2.5 + 2.5 g, intravenous) 2 h after the last administration of dabigatran etexilate. RESULTS: ) in the presence and absence of idarucizumab was close to zero for all coagulation parameters, diluted thrombin time (dTT), ecarin clotting time (ECT), activated partial thromboplastin time (aPTT), and thrombin time (TT), which indicated the reversal of dabigatran anticoagulation by idarucizumab. There were no serious adverse events reported in this study. No subject tested positive for anti-idarucizumab antibodies. CONCLUSION: Idarucizumab was well tolerated and no subject tested positive for anti-idarucizumab antibodies in this study. PK and PD of idarucizumab in healthy Chinese subjects at a steady state of dabigatran were comparable with those in Japanese and Caucasian subjects. CLINICAL REGISTRATION: ClinicalTrials.gov Identifier No. NCT03086356.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2020) studied Healthy volunteers (n=12). Idarucizumab vs. Dabigatran etexilate alone was evaluated on Area under the plasma concentration-time curve (AUC0-∞) of idarucizumab. Idarucizumab administration resulted in immediate, complete, and sustained reversal of the dabigatran-induced anticoagulant effect in healthy Chinese subjects, decreasing the area under the effect curve by ≥98% for all coagulation parameters.
Synapse has enriched 10 related papers. Consider them for comparative context: